Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its ...

A vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to be free of the toxicity that has scuppered earlier candidates. To be clear, there ...

UK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes spectrum manage their condition. The app – called DBm-Health – can help users to ...

Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution ...

Innovent prepares to file GLP-1/glucagon agonist mazdutide in China for diabetes, its second indication after obesity.

Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional ...

Explore how gamification and innovative technologies can revolutionise medical education, making learning more engaging and effective. Discover the benefits and best practices for integrating ...

New guidance from the EMA has introduced a shift in thinking at the regulator on the inclusion of pregnant and breastfeeding women in clinical trials. The new document, which is open for public ...

In the next part of his series on the history of the pharmaceutical industry, Robin Walsh looks at the biggest company of them all – Pfizer. Pfizer was founded in 1849 by two recent German ...

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.

The delayed meeting of the CDC's main vaccines advisory committee has taken place, with new recommendations on respiratory syncytial virus (RSV) vaccines that do away with restrictions imposed ...

Watch the recording of our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’.